Revenue and Profit - Revenue for Q3 2022 reached ¥575,087,948.20, an increase of 11.97% year-over-year, while year-to-date revenue totaled ¥1,370,691,220.82, up 20.59% compared to the same period last year[7]. - Net profit attributable to shareholders for Q3 2022 was ¥167,852,734.59, reflecting a 1.70% increase year-over-year, with a year-to-date net profit of ¥455,464,130.48, up 16.73%[7]. - Basic earnings per share for Q3 2022 were ¥0.38, up 2.70% year-over-year, while diluted earnings per share also stood at ¥0.38[7]. - Total operating revenue for the current period reached ¥1,370,691,220.82, an increase of 20.6% compared to ¥1,136,643,420.66 in the previous period[28]. - Net profit for the current period was ¥455,464,130.48, representing a 16.7% increase from ¥390,176,301.10 in the previous period[30]. - Basic and diluted earnings per share were both ¥1.04, compared to ¥0.89 in the previous period[33]. Cash Flow and Liquidity - The company's cash flow from operating activities showed a significant decline, with a year-to-date net cash flow of ¥82,185,693.73, down 47.55% compared to the previous year[7]. - Cash flow from operating activities totaled ¥1,274,245,066.13, a decrease from ¥1,417,676,860.54 in the previous period[34]. - The net cash flow from operating activities was 82,185,693.73, a decrease of 47.5% compared to 156,679,118.33 from the previous period[37]. - The total cash and cash equivalents at the end of the period were 144,734,657.17, down from 623,880,152.83, reflecting a significant decrease[37]. - The company's cash and cash equivalents decreased to CNY 184.01 million from CNY 442.26 million, representing a decline of approximately 58.4%[21]. Assets and Liabilities - Total assets increased to ¥5,605,973,210.82, representing a growth of 20.24% from the end of the previous year[7]. - The total assets amounted to ¥5,605,973,210.82, compared to ¥4,662,239,616.98 in the previous period[27]. - The company's equity attributable to shareholders rose to ¥2,867,008,388.53, marking a 12.80% increase from the end of the previous year[7]. - The total liabilities reached ¥2,738,964,822.29, an increase from ¥2,120,484,168.47 in the previous period[27]. - The company’s total liabilities increased to CNY 1.16 billion, compared to CNY 1.04 billion, representing a rise of about 11.3%[24]. Accounts Receivable and Inventory - Accounts receivable increased by 42.20% to ¥1,245,343,655.06, attributed to the expansion of business scale[12]. - Accounts receivable increased significantly to CNY 1.25 billion, up from CNY 875.76 million, indicating a growth of around 42.2%[21]. - Inventory levels rose by 46.57% to ¥384,257,012.35, indicating an increase in raw material stockpiling[12]. - Inventory rose to CNY 384.26 million, compared to CNY 262.17 million, marking an increase of approximately 46.5%[24]. Borrowings and Financing - Long-term borrowings surged by 248.78% to ¥639,557,744.96, reflecting increased financing activities[12]. - The company's short-term borrowings increased to CNY 538.29 million from CNY 347.11 million, reflecting a rise of about 55.0%[24]. - The net cash flow from financing activities was 477,193,943.52, a decrease of 47.4% from 905,996,049.53 in the previous period[37]. Government Subsidies and Expenses - The company reported government subsidies of ¥21,147,279.58 year-to-date, an increase of 185.19% compared to the previous year[12]. - Research and development expenses amounted to ¥258,238,348.53, up from ¥204,105,266.69 in the previous period[30]. - Financial expenses increased significantly to ¥63,728,301.67, compared to ¥27,098,855.39 in the previous period[30]. - The cash paid for various taxes was 198,727,567.27, up from 116,900,148.43, representing an increase of 69.9%[37]. - The cash paid to employees and for employee benefits was 121,984,431.11, compared to 77,817,173.17, marking an increase of 56.6%[37].
普利制药(300630) - 2022 Q3 - 季度财报